Medtronic PLC $MDT Stock Position Lessened by Confluence Investment Management LLC

Confluence Investment Management LLC decreased its position in shares of Medtronic PLC (NYSE:MDT) by 10.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 174,010 shares of the medical technology company’s stock after selling 21,230 shares during the period. Confluence Investment Management LLC’s holdings in Medtronic were worth $15,015,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of MDT. Envestnet Portfolio Solutions Inc. increased its position in Medtronic by 17.4% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 73,993 shares of the medical technology company’s stock valued at $5,788,000 after buying an additional 10,960 shares in the last quarter. State Street Corp boosted its holdings in Medtronic by 2.7% in the second quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock worth $5,005,320,000 after acquiring an additional 1,658,301 shares in the last quarter. Security National Bank of Sioux City Iowa IA purchased a new stake in shares of Medtronic during the second quarter worth about $48,000. Wellington Altus USA Inc. increased its holdings in shares of Medtronic by 18.1% during the second quarter. Wellington Altus USA Inc. now owns 2,294 shares of the medical technology company’s stock valued at $199,000 after acquiring an additional 351 shares in the last quarter. Finally, Bullseye Investment Management LLC acquired a new position in shares of Medtronic during the second quarter valued at about $45,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently commented on MDT. UBS Group lifted their target price on shares of Medtronic from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, September 3rd. Leerink Partners decreased their price target on shares of Medtronic from $117.00 to $104.00 and set an “outperform” rating for the company in a report on Thursday, June 4th. TD Cowen reiterated a “buy” rating and set a $110.00 price objective on shares of Medtronic in a research note on Wednesday. Needham & Company LLC reissued a “buy” rating on shares of Medtronic in a report on Thursday, September 17th. Finally, Evercore set a $105.00 target price on Medtronic in a research report on Monday, July 6th. Nineteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, Medtronic has a consensus rating of “Moderate Buy” and a consensus target price of $103.92.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic announced FDA clearance and CE Mark milestones for its Affera Prism-2 Mapping Software, along with CE Mark approval for the PulseSelect ProxBox Adapter. The approvals expand the company’s cardiac ablation and mapping capabilities and could support adoption of its electrophysiology portfolio. Medtronic announces regulatory milestones for newest cardiac mapping and ablation software
• Positive Sentiment: The FDA cleared Medtronic’s LigaSure RAS Maryland jaw for use with its Hugo robotic-assisted surgery system in the United States. The device broadens Hugo’s instrument lineup and may make the platform more attractive to hospitals evaluating robotic surgery systems. Medtronic receives FDA clearance for LigaSure RAS device
• Positive Sentiment: TD Cowen reaffirmed its “buy” rating and assigned a $110 price target, implying substantial upside from recent trading levels. The endorsement supports the view that Medtronic’s valuation and product pipeline remain attractive. TD Cowen rating update
• Neutral Sentiment: Commentary from Motley Fool and Zacks describes Medtronic as a potentially attractive long-term value stock, citing its valuation, financial profile and strategy. These opinions may support investor interest but do not represent new company-specific catalysts.
• Neutral Sentiment: Medtronic’s William J. Peine was named the 2026 Inventor of the Year for patented innovations related to the Hugo robotic-assisted surgery system. The recognition highlights research strength but has limited immediate earnings impact. IPO Education Foundation names Medtronic inventor of the year
• Negative Sentiment: Put-option volume rose about 45% above its average, indicating increased bearish speculation or downside hedging. This options activity may be contributing to short-term weakness, although it does not by itself confirm a fundamental deterioration.

Medtronic Stock Performance

NYSE:MDT traded down $0.31 during mid-day trading on Thursday, hitting $85.98. The company’s stock had a trading volume of 13,134,591 shares, compared to its average volume of 9,199,728. The stock has a market cap of $109.98 billion, a price-to-earnings ratio of 21.16, a PEG ratio of 1.98 and a beta of 0.56. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The business’s fifty day moving average is $90.00 and its two-hundred day moving average is $84.78. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.39 by $0.06. The business had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%.The business’s quarterly revenue was up 13.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Analysts anticipate that Medtronic PLC will post 5.98 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 3.3%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic’s dividend payout ratio is presently 70.94%.

Insider Activity at Medtronic

In related news, EVP Harry Kiil sold 1,483 shares of Medtronic stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total value of $138,882.95. Following the completion of the transaction, the executive vice president owned 42,186 shares in the company, valued at $3,950,718.90. The trade was a 3.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.27% of the stock is owned by company insiders.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.